Cargando…

Longitudinal analysis of cell-free mutated KRAS and CA 19–9 predicts survival following curative resection of pancreatic cancer

BACKGROUND: Novel biomarkers and molecular monitoring tools hold potential to improve outcome for patients following resection of pancreatic ductal adenocarcinoma (PDAC). We hypothesized that the combined longitudinal analysis of mutated cell-free plasma KRAS (cfKRAS(mut)) and CA 19–9 during adjuvan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussung, Saskia, Akhoundova, Dilara, Hipp, Julian, Follo, Marie, Klar, Rhena F. U., Philipp, Ulrike, Scherer, Florian, von Bubnoff, Nikolas, Duyster, Justus, Boerries, Melanie, Wittel, Uwe, Fritsch, Ralph M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802224/ https://www.ncbi.nlm.nih.gov/pubmed/33430810 http://dx.doi.org/10.1186/s12885-020-07736-x

Ejemplares similares

Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures
por: Braun, Lukas M., et al.
Publicado: (2020)

Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma
por: Rittmann, Marie-Claire, et al.
Publicado: (2021)

Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management
por: Wehrle, Julius, et al.
Publicado: (2020)

Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma
por: Klett, Hagen, et al.
Publicado: (2018)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
por: Waldeck, Silvia, et al.
Publicado: (2020)

Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylation
por: Kancha, Rama Krishna, et al.
Publicado: (2013)

Development of Highly Sensitive Digital Droplet PCR for Detection of cKIT Mutations in Circulating Free DNA That Mediate Resistance to TKI Treatment for Gastrointestinal Stromal Tumor (GIST)
por: Rassner, Michael, et al.
Publicado: (2023)

Oncologist’s/haematologist’s view on the roles of pathologists for molecular targeted cancer therapy
por: Keller, Ulrich, et al.
Publicado: (2010)

ROS1 genomic rearrangements are rare actionable drivers in microsatellite stable colorectal cancer
por: Akhoundova, Dilara, et al.
Publicado: (2022)

Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
por: Kulemann, Birte, et al.
Publicado: (2017)

Curative-intent pancreas resection for pancreatic metastases: surgical and oncological results
por: Chikhladze, Sophia, et al.
Publicado: (2020)

Differential Sensitivity of ERBB2 Kinase Domain Mutations towards Lapatinib
por: Kancha, Rama Krishna, et al.
Publicado: (2011)

Author Correction: Pancreatic cancer: Circulating Tumor Cells and Primary Tumors show Heterogeneous KRAS Mutations
por: Kulemann, Birte, et al.
Publicado: (2017)

Sensitivity and Resistance of Oncogenic RAS-Driven Tumors to Dual MEK and ERK Inhibition
por: Catalano, Antonella, et al.
Publicado: (2021)

Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
por: von Bubnoff, Nikolas, et al.
Publicado: (2018)

Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2020)

Correction: Colon and liver tissue damage detection using methylated SESN3 and PTK2B genes in circulating cell-free DNA in patients with acute graft-versus-host disease
por: Waterhouse, Miguel, et al.
Publicado: (2021)

Early assessment of circulating tumor DNA after curative‐intent resection predicts tumor recurrence in early‐stage and locally advanced non‐small‐cell lung cancer
por: Waldeck, Silvia, et al.
Publicado: (2021)

Targeting ALK in Neuroendocrine Tumors of the Lung
por: Akhoundova, Dilara, et al.
Publicado: (2022)

Inhibition of Aurora Kinase B Is Important for Biologic Activity of the Dual Inhibitors of BCR-ABL and Aurora Kinases R763/AS703569 and PHA-739358 in BCR-ABL Transformed Cells
por: Illert, Anna L., et al.
Publicado: (2014)

Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo
por: Schnerch, Dominik, et al.
Publicado: (2017)

Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma
por: Dold, Sandra Maria, et al.
Publicado: (2020)

Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience
por: Hoefflin, Rouven, et al.
Publicado: (2018)

CXCR4, CXCR5 and CD44 May Be Involved in Homing of Lymphoma Cells into the Eye in a Patient Derived Xenograft Homing Mouse Model for Primary Vitreoretinal Lymphoma
por: Babst, Neele, et al.
Publicado: (2022)

Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma
por: Dierks, Christine, et al.
Publicado: (2021)

Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)

β(6)-Integrin Serves as a Potential Serum Marker for Diagnosis and Prognosis of Pancreatic Adenocarcinoma
por: Lenggenhager, Daniela, et al.
Publicado: (2021)

Sequential Treatment of Metastatic Adenocarcinoma of the Pancreatic Duct with Liver Metastasis Following the NAPOLI-1 Study Protocol with nal-Irinotecan plus 5-FU in the Second Line
por: Akhoundova Sanoyan, Dilara, et al.
Publicado: (2020)

Significance of druggable targets (PD-L1, KRAS, BRAF, PIK3CA, MSI, and HPV) on curatively resected esophageal squamous cell carcinoma
por: Lee, Hong Kyu, et al.
Publicado: (2020)

Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome
por: Lakomy, Tim, et al.
Publicado: (2023)

Oncogenic Kras(G12D) causes myeloproliferation via NLRP3 inflammasome activation
por: Hamarsheh, Shaima’a, et al.
Publicado: (2020)

The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
por: Charlet, Anne, et al.
Publicado: (2021)

Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients
por: Sanoyan, Dilara Akhoundova, et al.
Publicado: (2023)

CAR-T Cell Therapy Shows Similar Efficacy and Toxicity in Patients With DLBCL Regardless of CNS Involvement
por: Shumilov, Evgenii, et al.
Publicado: (2023)

Efficacy and Safety of High-Dose Chemotherapy with Treosulfan and Melphalan in Multiple Myeloma
por: Gillich, Cédric, et al.
Publicado: (2023)

CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma
por: Wittibschlager, Valerie, et al.
Publicado: (2023)

Exceptional Response to Pembrolizumab in a Mismatch Repair-Deficient Aggressive Prostate Cancer with Somatic EPCAM, MSH2, and MSH6 Co-Deletion: A Case Report
por: Hoch, Dennis, et al.
Publicado: (2023)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression
por: Klein, Claudius, et al.
Publicado: (2016)

Is Computed-Tomography-Based Body Composition a Reliable Predictor of Chemotherapy-Related Toxicity in Pancreatic Cancer Patients?
por: Cefalì, Marco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0u6orihoe4odad1ctiem2qg238